VERTEX PHARMACEUTICALS INC / MA

VRTX · Nasdaq · SIC 2834: Pharmaceutical Preparations · Market Cap: $110.5B · 6,400 employees
85
SEC Filings
$438.4
Close 2026-06-01
2
Transcripts
6,400
Employees

Business Summary

Vertex Pharmaceuticals is a global biotechnology company focused on transformative medicines for serious diseases. It markets TRIKAFTA/KAFTRIO, ALYFTREK, SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO for cystic fibrosis; CASGEVY (gene-editing therapy) for sickle cell disease and transfusion-dependent beta thalassemia; and JOURNAVX (suzetrigine) for acute pain. The company also has a mid- and late-stage pipeline targeting IgA nephropathy, APOL1-mediated kidney disease, neuropathic pain, type 1 diabetes, primary membranous nephropathy, and other serious diseases.

Latest Stock Quote

VRTX 2026-06-01 $438.4 O:$439.91 H:$443.54 L:$433.2601 Vol:1.1M VWAP:$437.6747
origin leaf: 3928c8784281962a08d2e7fe67ef3bb272b057e7f916e9422dce1eaaa2e4757d

Next Earnings

expected 2026-08-07

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionVRTXdiscussed Artificial Intelligence
topic_mentionVRTXdiscussed Networking
topic_mentionVRTXdiscussed Regulation
topic_mentionVRTXdiscussed Sovereign & Government
topic_mentionVRTXdiscussed Automotive
topic_mentionVRTXdiscussed Healthcare & Bio
guidanceVRTXguided guidance relates primarily to $650 million
topic_mentionVRTXdiscussed Networking
topic_mentionVRTXdiscussed Regulation
topic_mentionVRTXdiscussed Sovereign & Government
topic_mentionVRTXdiscussed Automotive
topic_mentionVRTXdiscussed Healthcare & Bio
guidanceVRTXguided expectations for continued investment in multiple mid- and late-stage clinical development programs and commercial capabilities, and AIPR&D expenses of approximately $100 million
guidanceVRTXguided guidance relates primarily to $650 million

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-02-132025-12-310000875320-26-000056EDGAR68K words
2025-02-132024-12-310000875320-25-000053EDGAR—
2024-02-152023-12-310000875320-24-000062EDGAR—
2023-02-102022-12-310000875320-23-000007EDGAR—
2022-02-092021-12-310000875320-22-000007EDGAR—
2021-02-112020-12-310000875320-21-000006EDGAR—
2020-02-132019-12-310000875320-20-000007EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2026-05-052026-03-310000875320-26-000173EDGAR—
2025-11-042025-09-300000875320-25-000232EDGAR23K words
2025-08-052025-06-300000875320-25-000216EDGAR—
2025-05-062025-03-310000875320-25-000192EDGAR—
2024-11-052024-09-300000875320-24-000223EDGAR—
2024-08-022024-06-300000875320-24-000198EDGAR—
2024-05-072024-03-310000875320-24-000139EDGAR—
2023-11-072023-09-300000875320-23-000031EDGAR—
2023-08-022023-06-300000875320-23-000021EDGAR—
2023-05-022023-03-310000875320-23-000012EDGAR—
2022-10-282022-09-300000875320-22-000038EDGAR—
2022-08-052022-06-300000875320-22-000030EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-05-130000875320-26-000204EDGAR—
2026-05-040000875320-26-000171EDGAR—
2026-04-290000875320-26-000166EDGAR—
2026-03-310000875320-26-000147EDGAR1K words
2026-02-120000875320-26-000034EDGAR—
2025-11-030000875320-25-000230EDGAR—
2025-08-040000875320-25-000213EDGAR—
2025-05-190000875320-25-000199EDGAR—
2025-05-140000875320-25-000194EDGAR—
2025-05-050000875320-25-000171EDGAR—

85 total filings indexed. 56 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Earnings Transcripts

Call DateQuarterTitle
— VRTX Earnings Call Transcript
— VRTX Earnings Call Transcript

Access full transcripts via API (JSON) — includes speakers, key metrics, competitive mentions, and origin provenance chain.

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Tags

cystic-fibrosis sickle-cell-disease transfusion-dependent-beta-thalassemia acute-pain iga-nephropathy apol1-mediated-kidney-disease peripheral-neuropathic-pain type-1-diabetes primary-membranous-nephropathy autosomal-dominant-polycystic-kidney-disease myotonic-dystrophy-type-1 crispr/cas9-gene-editing cftr-modulation nav1.8-selective-inhibition allogeneic-stem-cell-derived-islet-cell-therapy

Company Identity

CIK0000875320
TickerVRTX
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedMA
Websitehttps://www.vrtx.com
Listed1991-07-31

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: c3189d8ab0cca1cfcf468a42f54f641ca373ddb2a3985e25ad43240ff21b2efc
parent: 427d9f34934c99de0a1093353bf8a228a5008e5deb4cc4bbe5e6a5e8403d2189
content hash: b90eb8b63084516d0140b32a856a8a5d241075c4ac2c11070f62d9234ce3754e
signed: 2026-06-02T19:03:04.237Z
sources: 22 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf